



ConvergeHEALTH Miner™

Provide visibility into information that exists within your organization and enable stakeholders to collaborate across the enterprise

The Industry Need

Significant advancements in science, vast increases in the amount and variety of data, and shifts in economic regulation and reimbursement are changing the dynamic in the healthcare ecosystem. The resulting trends in value-based care and precision medicine are accelerating the shift toward evidence generation, knowledge management systems, and the need for flexible scalable data storage and computing. Conveniently, significant improvements across the spectrum of information technology have occurred, especially in the areas of cloud computing, security, big data, and analytics, creating the perfect storm to provide life science organizations the opportunity to comprehensively improve the generation of evidence and maximize their business value.

ConvergeHEALTH Miner

The Miner solution from ConvergeHEALTH by Deloitte offers a modular suite of tools and services to accelerate evidence generation and management across the evidence life cycle. Miner's components help organizations unlock the full potential of their data. The solution can cross organizational groups, technology silos, and fragmented systems and processes.

Miner's technical components include Data Asset Explorer (DAE), Research Trust (RT), Cohort Builder (CB), Cohort Integrator (CI), and a library of visualization dashboards. These components can be combined or used separately as accelerators to empower users to visualize data and analyses, enhance collaboration, and manage their data assets. These capabilities can increase organizational efficiencies related to evidence generation. Miner enables life sciences companies to harness the full potential of their data and insights across their organization.

The Miner suite coupled with the industry depth of the consulting practice can be oriented towards:

Translational Informatics:



Enable big data solutions to optimize collection and utilization of clinical biosamples and enable complex phenotype and genotype analyses. Ultimately, identify new potential candidate molecules with higher probabilities to succeed.

Real World Evidence:



Empower knowledge management, collaboration management, and analytics to facilitate turning real world data into real world evidence. Demonstrating real world outcomes can justify price or complex reimbursement schemes.

Product and Portfolio Management:



Facilitate an effective transition to a metrics and data driven operation for all aspects of drug program and product management. This data driven approach can substantiate product investments and reduce late phase product failures.



Miner Components

Data Asset Explorer

Knowledge management and collaboration platform for organizations to unify assets sourced from data vendors proprietary sources with a rapid data characterization engine.

Research Trust

A data platform to hold and integrate health research and patient data to support downstream analytics and visualization applications in medical and translational research.

Cohort Integrator

Accelerates analytic workflows by enabling cohorts and subsets of phenotypic or genotypic data to be synchronized across multiple toolsets and platforms.

Cohort Builder

Accelerates analytic workflows by enabling cohort selection using phenotypic or genotypic data from multiple data sources on a cloud platform.

Sample Tracking Accelerator

An exploratory research tool coordinating end-to-end biomarker assays from planning & execution to analysis and close.

Visualization Dashboards

A series of syndicated reports and packaged guided analytics including Incidence & Prevalence, Burden of Disease, and Disease Progression that can be tailored to accelerate self-service.

Potential Impacts

The Miner product suite provides visibility into data sources, ongoing partnerships, and studies; enhances data governance; and fosters collaboration across the organization. These capabilities are foundational for an organization to understanding the breadth and depth of available data. Miner facilitates evidence generation to ultimately improve the quality of therapy and expedite the development process. Examples include:

- More efficient clinical trial planning
- Better insight into the probable success of a given asset for better portfolio results
- Enhanced ability to identify uses that can be researched for patent protection
- Improved adherence to safety and regulatory authorities
- Defined value argument for better reimbursement and approval outcomes

These changes can impact the overall business to increase on-patent revenue generation and contribute to a greater return on investment..

Start the conversation

To learn more about how Deloitte can help you get more from your data, visit us at www.deloitte.com or contact us directly:

David Hardison
VP Health Sciences
Deloitte Consulting LLP
dhardison@deloitte.com

Jeffrey Morgan
Specialist Leader
Deloitte Consulting LLP
jefmorgan@deloitte.com

Jinlei Liu
Product Manager
Deloitte Consulting LLP
jinliu@deloitte.com